Based on such links between acyl-CoA binding domains, their synthetase, and cancer, as well as our data that predicted a strong functional link between ACBD6 and NFκB via its inhibitors NFκB IA and NFκBIE (Pringle et al., 2012; Wu et al., 2006) (Fig. 2), we suggest a potential role of ACBD6 in prostate cancer as an upstream suppressor protein of NFκB activation. This evidence concerns the gene NFKB1 and prostate carcinoma.